Overwhelming response to heart disease study

Since launching recruitment for our EDCAD-PMS heart disease early detection study at the start of this week, we have had an overwhelming response, with hundreds of calls and emails. One of the biggest responses to our clinical trials ever.

Thank you so much to everyone who has contacted us about taking part in this trial. We are doing our best to respond as quickly as we can, and to help people work through the eligibility requirements for participation.

It is very exciting for us to see this level of interest in our heart disease research, and for it to resonate so strongly with the public. We know that finding better ways to understand heart disease risk and prevent its progression is top of mind for the family and friends of the many Australians who experience heart disease. The level of feedback we have had for this trial shows the incredibly high demand for more work to be done in this space.

Unfortunately, heart disease has been Australia’s number one killer for decades, but that needn’t be the case. With your support, we can find better ways to prevent, detect and treat heart disease.

If you are not eligible to participate in the EDCAD-PMS study but are interested in finding out more about some of the other clinical trials we currently have underway — many of which are also looking for people to take part — visit our clinical trials webpage.

If you would like to learn more about how you can support our innovative work to help reduce death and disability from heart disease, diabetes and other common cardiometabolic conditions, see how you can get involved or make a donation.

/Baker Institute Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.